Loading
LOADING
The cardiovascular outcomes trial (NCT05882045) is the one I'm most curious about. If reta shows MACE reduction comparable to or better than semaglutide's SELECT, that's the game-changer for adoption beyond pure obesity.
Phase 2 was 24.2% weight loss at 48 weeks. The dose-response wasn't plateauing. Phase 3 with longer duration could go higher. Or attrition kicks in, classic Phase 2 to 3 problem.
Thoughts on timeline? My guess is we see TRIUMPH-T2D readouts late 2026.
No comments yet. Start the thread.